Firebrick Pharma Signs License, Distribution Agreement to Sell Nasal Spray in Fiji, South Pacific, Shares Down 4%

MT Newswires Live

Feb 12, 2025

Firebrick Pharma (ASX:FRE) has signed a license and distribution agreement with Fiji Islands company Makans, under which Makans will immediately start to promote and sell the Nasodine nasal spray in Fiji and South Pacific, the company said in a Wednesday Australian bourse filing.

Under the deal, Makans will pay the company a manufacturing/handling fee equivalent to 20% of the cost of goods of licensed products supplied by the company and also a fee of AU$1.80 per unit of licensed products sold.

The Company expects an initial order from Makans of approximately 1,000 units of Nasodine, the filing said.

The agreement is for an initial term of one year renewable for successive one-year terms, the filing added.

Company shares were down 4% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2510196397"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510196397\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510196397?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-12 11:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510196397","market":"hk","top_or_hot":-1,"title":"Firebrick Pharma Signs License, Distribution Agreement to Sell Nasal Spray in Fiji, South Pacific, Shares Down 4%","media":"MT Newswires Live","content":"<html><body><p> Firebrick Pharma (ASX:FRE) has signed a license and distribution agreement with Fiji Islands company Makans, under which Makans will immediately start to promote and sell the Nasodine nasal spray in Fiji and South Pacific, the company said in a Wednesday Australian bourse filing.</p><p>Under the deal, Makans will pay the company a manufacturing/handling fee equivalent to 20% of the cost of goods of licensed products supplied by the company and also a fee of AU$1.80 per unit of licensed products sold.</p><p>The Company expects an initial order from Makans of approximately 1,000 units of Nasodine, the filing said.</p><p>The agreement is for an initial term of one year renewable for successive one-year terms, the filing added.</p><p>Company shares were down 4% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Firebrick Pharma Signs License, Distribution Agreement to Sell Nasal Spray in Fiji, South Pacific, Shares Down 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFirebrick Pharma Signs License, Distribution Agreement to Sell Nasal Spray in Fiji, South Pacific, Shares Down 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-12 11:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Firebrick Pharma (ASX:FRE) has signed a license and distribution agreement with Fiji Islands company Makans, under which Makans will immediately start to promote and sell the Nasodine nasal spray in Fiji and South Pacific, the company said in a Wednesday Australian bourse filing.</p><p>Under the deal, Makans will pay the company a manufacturing/handling fee equivalent to 20% of the cost of goods of licensed products supplied by the company and also a fee of AU$1.80 per unit of licensed products sold.</p><p>The Company expects an initial order from Makans of approximately 1,000 units of Nasodine, the filing said.</p><p>The agreement is for an initial term of one year renewable for successive one-year terms, the filing added.</p><p>Company shares were down 4% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2510196397","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510196397","pubTimestamp":1739330639,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Firebrick Pharma (ASX:FRE) has signed a license and distribution agreement with Fiji Islands company Makans, under which Makans will immediately start to promote and sell the Nasodine nasal spray in F","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","FRE.AU":"FIREBRICK PHARMA LTD"},"translate_title":"Firebrick Pharma签署在南太平洋斐济销售鼻喷雾剂的许可和分销协议，股价下跌4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FRE.AU":0.9},"content_text":"Firebrick Pharma (ASX:FRE) has signed a license and distribution agreement with Fiji Islands company Makans, under which Makans will immediately start to promote and sell the Nasodine nasal spray in Fiji and South Pacific, the company said in a Wednesday Australian bourse filing.Under the deal, Makans will pay the company a manufacturing/handling fee equivalent to 20% of the cost of goods of licensed products supplied by the company and also a fee of AU$1.80 per unit of licensed products sold.The Company expects an initial order from Makans of approximately 1,000 units of Nasodine, the filing said.The agreement is for an initial term of one year renewable for successive one-year terms, the filing added.Company shares were down 4% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}